RxDoctor Payments Data

Kiran Kashyap, MD

Cardiovascular Disease · Menomonee Falls, WINPI 1134192115

Payments from drug & device makers

$1,325in general payments, 2019–2025

Across 61 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$280
  • Medtronic$256
  • Amgen$187
  • AstraZeneca$147
  • Boston Scientific$103
  • Novartis$83
  • plus $269 from 8 others

What the payments were for

  • Food & beverage$1,325100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,325 in reported general payments places this provider in the 50th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$166,368
Medicare patients
923
Services billed
2,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban356$425,208
FarxigaDapagliflozin Propanediol173$219,462
EntrestoSacubitril/Valsartan107$142,310
Repatha SureclickEvolocumab93$83,555
JardianceEmpagliflozin33$50,240
XareltoRivaroxaban29$30,990
VascepaIcosapent Ethyl20$18,643
Metoprolol Succinate724$9,154
Atorvastatin Calcium716$6,999
Ezetimibe321$5,602
Isosorbide Mononitrate ErIsosorbide Mononitrate449$5,125
Ranolazine ErRanolazine55$4,608
ClopidogrelClopidogrel Bisulfate260$3,520
Midodrine Hcl19$3,163
Rosuvastatin Calcium278$2,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$147$219,462173 claims
NovartisEntresto$83$142,310107 claims
Boehringer IngelheimJardiance$32$50,24033 claims
Johnson & JohnsonXarelto$25$30,99029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Menomonee Falls

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →